Quick Answer
Galera Therapeutics, Inc. reported Net Income Loss of $149.05 million for the year ending 2025.
- Galera Therapeutics, Inc. showed an increase of +886.2% in Net Income Loss from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.53 million | Q2 2018: -$4.33 million | Q3 2018: -$5.25 million | Q1 2019: -$10.35 million | Q2 2019: -$11.56 million | Q3 2019: -$13.35 million | Q1 2020: -$18.42 million | Q2 2020: -$18.66 million | Q3 2020: -$17.08 million | Q1 2021: -$18.72 million | Q2 2021: -$22.39 million | Q3 2021: -$22.63 million | Q1 2022: -$15.44 million | Q2 2022: -$14.56 million | Q3 2022: -$16.03 million | Q1 2023: -$17.71 million | Q2 2023: -$20.71 million | Q3 2023: -$15.07 million | Q1 2024: -$4.38 million | Q2 2024: -$4.06 million | Q3 2024: -$5.58 million | Q1 2025: -$1.59 million | Q2 2025: -$1.08 million | Q3 2025: -$1.39 million.
- Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Net Income Loss has grown by 729.5%.
- Historical annual values: Fiscal year 2025: $149.05 million | Fiscal year 2024: -$18.96 million | Fiscal year 2023: -$59.08 million | Fiscal year 2022: -$62.22 million | Fiscal year 2021: -$80.53 million | Fiscal year 2020: -$74.22 million | Fiscal year 2019: -$51.93 million | Fiscal year 2018: -$23.68 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: